SGP Valuation

SpyGlass Pharma Inc (SGP) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of --. The fair price of SpyGlass Pharma Inc (SGP) is between -- to -- according to relative valuation method.

SGP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of SpyGlass Pharma Inc (SGP) is between -- to -- according to relative valuation method.

The average P/S ratio for SGP's competitors is 30.16, providing a benchmark for relative valuation. SpyGlass Pharma Inc Corp (SGP) exhibits a P/S ratio of --, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

As of Mar 03 2026, SpyGlass Pharma Inc (SGP) has a P/B ratio of NaN. This indicates that the market values SGP at NaN times its book value.

As of Mar 03 2026, SpyGlass Pharma Inc (SGP) has a FCF Yield of NaN%. This means that for every dollar of SpyGlass Pharma Inc's market capitalization, the company generates NaN cents in free cash flow.

As of Mar 03 2026, SpyGlass Pharma Inc (SGP) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of SpyGlass Pharma Inc's expected earnings over the next 12 months.

As of Mar 03 2026, SpyGlass Pharma Inc (SGP) has a Forward P/S ratio of NaN. This means the market is valuing SGP at $NaN for every dollar of expected revenue over the next 12 months.